دورية أكاديمية
أعرض في EDS

ALDH3A2 , ODF2 , QSOX2 , and MicroRNA-503-5p Expression to Forecast Recurrence in TMPRSS2-ERG -Positive Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: ALDH3A2 , ODF2 , QSOX2 , and MicroRNA-503-5p Expression to Forecast Recurrence in TMPRSS2-ERG -Positive Prostate Cancer.
المؤلفون: Kobelyatskaya AA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Kudryavtsev AA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Kudryavtseva AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Snezhkina AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Fedorova MS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Kalinin DV; Vishnevsky Institute of Surgery, Ministry of Health of the Russian Federation, 117997 Moscow, Russia., Pavlov VS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Guvatova ZG; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Naberezhnev PA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Nyushko KM; National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284 Moscow, Russia., Alekseev BY; National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284 Moscow, Russia., Krasnov GS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Bulavkina EV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Pudova EA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Oct 02; Vol. 23 (19). Date of Electronic Publication: 2022 Oct 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: MicroRNAs*/genetics , Prostatic Neoplasms*/metabolism, Heat-Shock Proteins ; Humans ; Male ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Oncogene Proteins, Fusion/genetics ; Oxidoreductases Acting on Sulfur Group Donors ; RNA, Messenger ; Serine Endopeptidases ; Transcriptional Regulator ERG
مستخلص: Following radical surgery, patients may suffer a relapse. It is important to identify such patients so that therapy tactics can be modified appropriately. Existing stratification schemes do not display the probability of recurrence with enough precision since locally advanced prostate cancer (PCa) is classified as high-risk but is not ranked in greater detail. Between 40 and 50% of PCa cases belong to the TMPRSS2-ERG subtype that is a sufficiently homogeneous group for high-precision prognostic marker search to be possible. This study includes two independent cohorts and is based on high throughput sequencing and qPCR data. As a result, we have been able to suggest a perspective-trained model involving a deep neural network based on both qPCR data for mRNA and miRNA and clinicopathological criteria that can be used for recurrence risk forecasts in patients with TMPRSS2-ERG-positive, locally advanced PCa (the model uses ALDH3A2 + ODF2 + QSOX2 + hsa-miR-503-5p + ISUP + pT, with an AUC = 0.944). In addition to the prognostic model's use of identified differentially expressed genes and miRNAs, miRNA-target pairs were found that correlate with the prognosis and can be presented as an interactome network.
References: Crit Rev Oncol Hematol. 2017 Dec;120:180-193. (PMID: 29198331)
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. (PMID: 22736790)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Nat Commun. 2021 Mar 5;12(1):1454. (PMID: 33674602)
BMC Med. 2016 Apr 04;14:67. (PMID: 27044421)
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7. (PMID: 24297251)
Med Sci Monit. 2019 Feb 11;25:1122-1132. (PMID: 30741252)
Histochem Cell Biol. 2021 Mar;155(3):423-433. (PMID: 33331954)
Dev Cell. 2009 Apr;16(4):539-50. (PMID: 19386263)
Front Cell Dev Biol. 2021 Jul 19;9:688798. (PMID: 34350181)
Cell Prolif. 2017 Apr;50(2):. (PMID: 27976428)
Cancer Inform. 2016 Sep 22;15(Suppl 4):11-7. (PMID: 27688707)
OMICS. 2021 Sep;25(9):545-566. (PMID: 34448651)
Nucleic Acids Res. 2014;42(17):e133. (PMID: 25063298)
Mol Biol (Mosk). 2011 Mar-Apr;45(2):238-48. (PMID: 21634111)
Front Genet. 2019 Mar 01;10:97. (PMID: 30881377)
Dis Model Mech. 2021 Apr 1;14(4):. (PMID: 33973623)
Life (Basel). 2021 Jun 21;11(6):. (PMID: 34205581)
Nat Rev Dis Primers. 2021 Feb 4;7(1):9. (PMID: 33542230)
Am J Surg Pathol. 2007 Jun;31(6):882-8. (PMID: 17527075)
EMBO Rep. 2018 Dec;19(12):. (PMID: 30413482)
Curr Oncol Rep. 2018 Jun 1;20(8):58. (PMID: 29858674)
JAMA. 1998 Sep 16;280(11):969-74. (PMID: 9749478)
Oncogene. 2016 Jan 28;35(4):403-14. (PMID: 25915839)
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (PMID: 27899662)
PLoS One. 2018 Oct 18;13(10):e0206239. (PMID: 30335862)
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503. (PMID: 31691815)
BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
NAR Genom Bioinform. 2021 Jul 21;3(3):lqab068. (PMID: 34308351)
Annu Rev Med. 2016;67:119-35. (PMID: 26515982)
Biomed Pharmacother. 2020 Apr;124:109863. (PMID: 31986411)
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612. (PMID: 33237311)
Pathol Res Pract. 2019 Oct;215(10):152593. (PMID: 31471104)
Exp Mol Pathol. 2021 Dec;123:104688. (PMID: 34592197)
Nature. 2009 Feb 12;457(7231):E1; discussion E2-3. (PMID: 19212347)
APMIS. 2017 Feb;125(2):101-105. (PMID: 28028835)
J Biol Chem. 2002 Dec 13;277(50):48696-707. (PMID: 12374789)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820948062. (PMID: 33063634)
PLoS One. 2014 Feb 05;9(2):e86824. (PMID: 24505269)
Eur Urol. 2018 Apr;73(4):572-582. (PMID: 29129398)
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338. (PMID: 30395331)
Int J Biol Sci. 2020 Jul 19;16(14):2628-2647. (PMID: 32792861)
Mol Biosyst. 2016 Feb;12(2):477-9. (PMID: 26661513)
Front Cell Dev Biol. 2021 Nov 10;9:678770. (PMID: 34858968)
Biochim Biophys Acta. 2005 May 25;1755(1):37-69. (PMID: 15907591)
معلومات مُعتمدة: 18-75-10127 Russian Science Foundation
فهرسة مساهمة: Keywords: RNA-Seq; TMPRSS2-ERG; expression; forecasting; miRNA-Seq; neural network; primary tumor; prostate cancer; recurrence; subtype
المشرفين على المادة: 0 (ERG protein, human)
0 (Heat-Shock Proteins)
0 (MIRN503 microRNA, human)
0 (MicroRNAs)
0 (ODF2 protein, human)
0 (Oncogene Proteins, Fusion)
0 (RNA, Messenger)
0 (TMPRSS2-ERG fusion protein, human)
0 (Transcriptional Regulator ERG)
EC 1.8.- (Oxidoreductases Acting on Sulfur Group Donors)
EC 1.8.3.2 (QSOX2 protein, human)
EC 3.4.21.- (Serine Endopeptidases)
EC 3.4.21.- (TMPRSS2 protein, human)
تواريخ الأحداث: Date Created: 20221014 Date Completed: 20221017 Latest Revision: 20221019
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9569942
DOI: 10.3390/ijms231911695
PMID: 36232996
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms231911695